EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC

Xiangye Ou, Jinhai Li, Rongjian Pan, Deyi Liu, Jiayi Wu, Dong Liang, Yinan Li, Zhenxin Zeng, Han Li, Yuxuan Zhang, Junyi Wu, Maolin Yan iD

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 21.04.2026. Verfasst von Xiangye Ou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350004, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phenylurea Compounds, Liver Neoplasms, Quinolines. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fujian Provincial Science and Technology Project, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and the rate of complete response in uHCC following triple therapy is relatively low. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.

Methods

This retrospective study included 29 patients with uHCC who received sequential radiotherapy after achieving partial response (PR) or stable disease (SD) in tumor response per the modified Response Evaluation Criteria in Solid Tumors (mRECIST) after triple therapy. The overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were analyzed to evaluate the efficacy of this regimen. Treatment-related adverse events were assessed to determine the safety profile.

Results

Among the 29 patients, the median OS had not yet been reached, and the median PFS was 19.43 months. The 24-month OS and PFS rates were 72.8% and 46.5%, respectively. The lesions of 6 patients initially with tumor response of PR achieved complete response, and the lesions of 12 patients with SD achieved PR after sequential radiotherapy. All adverse events were manageable, and no treatment-related death occurred.

Conclusion

Sequential radiotherapy after triple therapy enhanced tumor response and survival benefits for uHCC patients, with manageable adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularPhenylurea CompoundsLiver NeoplasmsQuinolinesChemoembolization, TherapeuticHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultCombined Modality TherapyProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

hepatocellular carcinomaimmunotherapyradiotherapytargeted therapytranscatheter arterial chemoembolization

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350004, China.
  • Department of Hepatobiliary Pancreatic Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325200, China.
  • Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, 350001, China.
  • The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian Province, 350000, China.

ORCID-Profile: Maolin Yan

Förderung

  • Fujian Provincial Science and Technology Project
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Ou, X., Li, J., Pan, R., Liu, D., Wu, J., Liang, D., Li, Y., Zeng, Z., Li, H., Zhang, Y., Wu, J., & Yan, M. (2026). The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag138

Vancouver

Ou X, Li J, Pan R, Liu D, Wu J, Liang D, et al. The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag138

BibTeX
@article{Ou2026,
  author = {Ou, Xiangye and Li, Jinhai and Pan, Rongjian and Liu, Deyi and Wu, Jiayi and Liang, Dong and Li, Yinan and Zeng, Zhenxin and Li, Han and Zhang, Yuxuan and Wu, Junyi and Yan, Maolin},
  title = {The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag138}
}
Kostenlos starten →